范科米辛的药理动力学和定制剂量在血液恶性病的成年患者:状态,挑战和机会
Xiangqing Song1, Meizi Zeng1, Tao Yang1
1Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Pharmacology research & perspectives
|January 31, 2026
概括
针对癌症患者进行定制的万科米辛 (VAN) 剂量非常重要,因为血液恶性瘤的药理动力学发生了变化. 本综述探讨了先进的VAN剂量技术,以优化治疗和对抗这种独特人群的耐药性.
科学领域:
- 药理学和传染病的研究
- 在瘤学瘤学.
- 临床药房 临床药房
背景情况:
- 香草素 (Vancomycin,简称VAN) 对于治疗耐药性格拉姆阳性感染,包括癌症患者的治疗至关重要.
- 血液性恶性瘤 (HMs) 改变了万科米辛的药理动力学 (PK),影响了安全性,疗效和耐药性.
- 目前的万科米辛剂量缺乏针对成人HM患者的具体指导方针.
研究的目的:
- 在成人HM患者中审查万科米辛PK和定制剂量 (CDvan) 技术.
- 探索在这个群体中实施CDvan的挑战和解决方案.
- 为了指导合理的万科米辛治疗和推进CDvan的开发.
主要方法:
- 在成人HM患者中进行的万科米辛PK研究的综合文献综述.
- 对人口PK模型的分析及其应用于万科米辛剂量的分析.
- 评估当前和新兴的CDvan技术 (TDM,模型引导,AI,闭环).
主要成果:
- 在HM患者中,VAN PK存在显著的患者间变异.
- 各种CDvan技术在优化VAN治疗方面表现有前途.
- 挑战包括数据集成和为CDvan实施制定指南.
结论:
- 个性化的万科米辛剂量对于改善成人HM患者的治疗结果至关重要.
- 先进的CDvan技术,包括AI和区块链,提供潜在的解决方案.
- 需要进一步的研究,以促进CDvan在HM患者中的广泛采用.
相关概念视频
01:15Drug Dosing: Geriatric Patients
272
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
272
01:21Drug Dosing: Obese Patients
263
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
675
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
675
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
279
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
279
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
261
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
261
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
304
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304